Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Background and aims
We have previously reported that the thrombolytic tenecteplase (TNK) is able to penetrate the retina following an intravitreal injection of 50 μg with no evidence of retinal toxicity.1–3 The purpose of this report, which is the first in humans, is to assess its efficacy and safety in the management of patients with submacular haemorrhage (SMH) secondary to age-related macular degeneration.
Eight patients with a fresh SMH ranging from 3 to 14 days due to age-related macular degeneration and with a reduction in vision to less than or equal to 20/200 were enrolled for this study.
Following topical anaesthesia and 5% povodine iodine solution preparation, 50 μg of commercial TNK (Metalyse, Boehringer, Ingelheim, NSW, Australia) diluted with balanced salt solution …
Funding The National Health and Medical Research Council of Australia and The Ophthalmic Research Institute of Australia.
Competing interests None.
Ethics approval Ethics approval was provided by the University of Western Australia Human Ethics Committee.
Patient consent Obtained.
Provenance and peer review Not commissioned; externally peer reviewed.